Kristin Mahan
Family · Uncasville, CTNPI 1750663860
Payments from drug & device makers
Across 411 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- GSK$772
- AstraZeneca$762
- Novo Nordisk$604
- Phathom Pharmaceuticals, Inc.$482
- Bausch Health US, LLC$254
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,823100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 164 | $2,920 |
| GSK | 35 | $772 |
| AstraZeneca(2 entities) | 26 | $762 |
| Novo Nordisk | 48 | $604 |
| Phathom Pharmaceuticals, Inc. | 19 | $482 |
| Bausch Health US, LLC | 14 | $254 |
| Astellas Pharma US Inc | 12 | $232 |
| Lilly USA, LLC | 11 | $218 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $214 |
| Pfizer | 8 | $138 |
| Biohaven Pharmaceuticals, Inc. | 7 | $121 |
| Boehringer Ingelheim | 6 | $120 |
| Sumitomo Pharma America, Inc. | 7 | $115 |
| Johnson & Johnson | 1 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $93 |
| Eisai Inc. | 5 | $81 |
| Exact Sciences | 4 | $78 |
| Myriad Women's Health, Inc. | 1 | $57 |
| Sunovion Pharmaceuticals Inc. | 8 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Scilex Pharmaceuticals Inc. | 2 | $44 |
| Abbott | 2 | $41 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Merck | 3 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Watermark Medical, Inc. | 2 | $35 |
| Evoke Pharma, Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Urovant Sciences Inc | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- NURTEC ODT$125
- AREXVY$125
- AIRSUPRA$120
- VRAYLAR$111
- SPRAVATO$106
- BREZTRI$102
How this compares
$7,853 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $181,605 |
| BotoxOnabotulinumtoxina | 67 | $76,140 |
| FarxigaDapagliflozin Propanediol | 40 | $59,953 |
| JanuviaSitagliptin Phosphate | 20 | $31,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $24,671 |
| JardianceEmpagliflozin | 15 | $24,027 |
| RybelsusSemaglutide | 14 | $22,636 |
| GemtesaVibegron | 24 | $21,851 |
| MyrbetriqMirabegron | 25 | $18,819 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $11,859 |
| EliquisApixaban | 13 | $8,406 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,423 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $7,092 |
| TradjentaLinagliptin | 12 | $6,532 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $604 | $204,241102 claims |
| AbbVieBotox, Combigan, Synthroid | $2,920 | $80,354106 claims |
| AstraZenecaFarxiga | $762 | $59,95340 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $772 | $43,95350 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $120 | $36,56938 claims |
| MerckJanuvia, Dulera | $37 | $35,99132 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $115 | $21,85124 claims |
| Astellas Pharma US IncMyrbetriq | $232 | $18,81925 claims |
| PfizerEliquis | $138 | $8,40613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Uncasville
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
- Ralph HirschfeldPutnam$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.